ClinicaliQ Trial Snapshot
- A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) — Active Not Recruiting • Phase III • Oncology • NCT06211764.
- TAR-200 compared to standard chemotherapy for bladder cancer recurrence after BCG in patients refusing surgery.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy. Conditions: Non-Muscle Invasive Bladder Neoplasms Interventions: TAR-200, Mitomycin C, Gemcitabine Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 272 participants